Integrin Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S8594	Tirofiban Hydrochloride	Tirofiban Hydrochloride (MK-383) is the hydrochloride salt form of tirofiban, a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation. It is more soluable than Tirofiban.	European Cells and Materials, May 11, 2020, 211-225 Translational Oncology, January 2024, 101813 Frontiers in Cellular and Infection Microbiology, December 6, 2021, 783085
S3714	Lifitegrast	Lifitegrast (SAR1118,SHP-606) is a novel small molecule integrin antagonist that inhibits a specific T cell-mediated inflammatory pathway involved in the pathogenesis of DED.	Med Oncol, 2024, 41(8):188 World Journal of Gastroenterology, 2023, 3103-3118 World J Gastroenterol, 2023, 29(20):3103-3118
S3085	Tirofiban	Tirofiban (MK-383) is a selective platelet GPIIb/IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.	Blood Advances, 2024, 99-111 Translational Oncology, 2024, 101813 Food Funct, 2020, 11(1):139-152
E0462	Pyrintegrin	Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival, also enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling.	Nat Commun, 2025, 16(1):5461 Signal Transduct Target Ther, 2024, 9(1):109
E4615	GLPG0187	GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. This compound also inhibits migrasome biogenesis without cytotoxicity. It exhibits potent antitumor activity.	Sci Rep, 2025, 15(1):9147 Scientific Reports, 2025, 9147
S6840	OSU-T315	OSU-T315 (ILK-IN-2) is a potent Integrin-Linked Kinase (ILK) inhibitor with IC50 of 0.6 μM. This compound induces autophagy and apoptosis, both of which are integral to its antiproliferative activity. It exhibits anti-tumor activity.	Exp Eye Res, 2023, 234:109609
E0790	ILK-IN-3	ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.	Nature Communications, April 06 2024, 15(1) Nature Communications, 2024, 2974
E1385	Bexotegrast (PLN-74809)	Bexotegrast(PLN-74809) is potent dual selective inhibitor of αvβ6 and αvβ1 integrins with Kd of 5.7 nM and 3.4 nM, respectively. It has antifibrogenic effects, blocks multiple TGF-β activation pathways in the fibrotic lung, and is useful for researching fibrosis, including idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).	European Journal of Pharmacology, 2024 Nov 15, 176983 European Journal of Pharmacology, 2024, 176983
E1558	GSK-3008348 HCl	GSK-3008348 HCl is a small molecule antagonist of integrin αvβ6 with an affinity (pIC50) value of 8.1 for αvβ6 in cell Adhesion assays.
S0314	TR-14035	TR-14035 (SB 683698, MDK-1191) is a a dual alpha4beta (α4β) integrin antagonist with IC50 of 7 nM and 87 nM for alpha4beta7 (α4β7) and alpha4beta1 (α4β1), respectively.
E7334	Cyclo(RGDyK)	Cyclo(RGDyK) is a potent and selective inhibitor of αVβ3 integrin . It significantly reduces lung inflammation and fibrosis induced by influenza A virus, and improves lung morphology, lowers pulmonary fibrosis scores, and suppresses the expression of αVβ3, TGF-β1, NF-κB p65, p38 MAPK, and HIF-1α, confirming its protective effects against ALI and pulmonary fibrosis.
E6559^New	GS-1427	GS-1427 (Emvistegrast) is an oral, small-molecule quinolone derivative that functions as a potent and selective antagonist of α4β7 integrin, with the potential treatment of inflammatory bowel disease.
E7759	GRGDSP	GRGDSP is a fibronectin-derived peptide and an inhibitor of Integrin. It can be used for surface modification of cardiovascular implants, such as vascular grafts, to promote endothelialization, and also holds potential for hepatocellular carcinoma (HCC) treatment by inhibiting tumor cell adhesion and limiting metastasis.
S3408	A286982	A-286982 is a potent, nonpeptide inhibitor of LFA-1/ICAM-1 interaction with IC50s of 44 nM and 35 nM in an LFA-1/ICAM-1 binding assay and LFA-1-mediated cellular adhesion assay, respectively.